RECCE PHARMACEUTICALS LTD - Investor Presentation 2021

ASX Announcement

==> picture [418 x 93] intentionally omitted <==

Recce Pharmaceuticals Presenting at the H.C. Wainwright Global Life Sciences Conference

Sydney Australia, 10 March 2021: Recce Pharmaceuticals Ltd ( ASX: RCE , FSE:R9Q ) ( Company ), the Company developing New Classes of Synthetic Anti-Infectives, today announced Chief Executive Officer James Graham is presenting an overview of the Company’s business, pipeline and recent corporate updates at the H.C Wainwright Global Life Sciences Conference. The virtual conference is held from March 9 – 10, 2021 (US Eastern Standard Time).

The event will incorporate a number of panel discussions, company presentations and oneon-one meetings with professionals within the investment and research industry.

A webcast and copy of the presentation will be available on the Company’s website and on demand to registered conference attendees. A copy of the presentation is also attached.

==> picture [338 x 112] intentionally omitted <==

For further information please contact:

Meredith Sosulski, Ph.D.

Media and Investor Relations (USA)

LifeSci Communications

+1 929 469 3851

[email protected]

This announcement has been approved for release by Recce Pharmaceuticals CEO.

==> picture [551 x 64] intentionally omitted <==

==> picture [76 x 49] intentionally omitted <==

==> picture [147 x 67] intentionally omitted <==

==> picture [61 x 38] intentionally omitted <==

March 2021

Disclaimer

==> picture [61 x 45] intentionally omitted <==

DISCLAIMER

This presentation has been prepared by Recce Pharmaceuticals Ltd (the “Company”). It does not purport to contain all the information that a prospective investor may require in connection with any

potential investment in the Company. You should not treat the contents of this presentation, or any information provided in connection with it, as financial advice, financial product advice or advice relating to legal, taxation or investment matters.

No representation or warranty (whether express or implied) is made by the Company or any of its officers, advisers, agents or employees as to the accuracy, completeness or reasonableness of the information, statements, opinions or matters (express or implied) arising out of, contained in or derived from this presentation or provided in connection with it, or any omission from this presentation, nor as to the attainability of any estimates, forecasts or projections set out in this presentation.

This presentation is provided expressly on the basis that you will carry out your own independent inquiries into the matters contained in the presentation and make your own independent decisions about the affairs, financial position or prospects of the Company. The Company reserves the right to update, amend or supplement the information at any time in its absolute discretion (without incurring any obligation to do so).

Neither the Company, nor its related bodies corporate, officers, their advisers, agents and employees accept any responsibility or liability to you or to any other person or entity arising out of this presentation including pursuant to the general law (whether for negligence, under statute or otherwise), or under the Australian Securities and Investments Commission Act 2001, Corporations Act 2001, Competition and Consumer Act 2010 or any corresponding provision of any Australian state or territory legislation (or the law of any similar legislation in any other jurisdiction), or similar provision under any applicable law. Any such responsibility or liability is, to the maximum extent permitted by law, expressly disclaimed and excluded. Nothing in this material should be construed as either an offer to sell or a solicitation of an offer to buy or sell securities. It does not include all available information and should not be used in isolation as a basis to invest in the Company.

FUTURE MATTERS

This presentation contains reference to certain intentions, expectations, future plans, strategy and prospects of the Company.

Those intentions, expectations, future plans, strategy and prospects may or may not be achieved. They are based on certain assumptions, which may not be met or on which views may differ and may be affected by known and unknown risks. The performance and operations of the Company may be influenced by a number of factors, many of which are outside the control of the Company. No representation or warranty, express or implied, is made by the Company, or any of its directors, officers, employees, advisers or agents that any intentions, expectations or plans will be achieved either totally or partially or that any particular rate of return will be achieved.

Given the risks and uncertainties that may cause the Company’s actual future results, performance or achievements to be materially different from those expected, planned or intended, recipients should not place undue reliance on these intentions, expectations, future plans, strategy and prospects. The Company does not warrant or represent that the actual results, performance or achievements will be as expected, planned or intended.

US DISCLOSURE

This document does not constitute any part of any offer to sell, or the solicitation of an offer to buy, any securities in the United States or to, or for the account or benefit of any “US person” as defined in Regulation S under the US Securities Act of 1993 (“Securities Act”). The Company’s shares have not been, and will not be, registered under the Securities Act or the securities laws of any state or other jurisdiction of the United States, and may not be offered or sold in the United States or to any US person without being so registered or pursuant to an exemption from registration including an exemption for qualified institutional buyers.

==> picture [61 x 38] intentionally omitted <==

==> picture [97 x 30] intentionally omitted <==

About Recce Pharmaceuticals Ltd

==> picture [61 x 45] intentionally omitted <==

==> picture [143 x 143] intentionally omitted <==

Listed on ASX 2016 (ASX:RCE)

Listed on FSE 2021

Unique and universal Mechanism of Action

Water soluble over a broad range of pH levels

Recce Pharmaceuticals (ASX:RCE) is commercialising a New Class of Synthetic Anti-Infectives to address the global health issue of antibiotic resistant superbugs and emerging viral pathogens.

==> picture [71 x 71] intentionally omitted <==

New Class of Synthetic Anti-Infectives that kill emerging viral pathogens as well as Gram + & Gram – bacteria, including their superbug forms - even with repeated use!

RECCE[®] 327 awarded Qualified Infectious Disease Product designation under GAIN Act

Patented manufacturing, producing to Phase I & II volumes

10 years market exclusivity (post approval)

RECCE[®] 327 & RECCE[®] 435 – bacterial indications

Fast track

(life of regulatory process)

RECCE[®] 529 – viral indications

==> picture [61 x 38] intentionally omitted <==

==> picture [97 x 30] intentionally omitted <==

Recce Pharmaceuticals Ltd - Capital Structure

Snapshot***

Major Shareholders – 2 March 2021
G & O Melrose*	23.6%
LDU Pty Ltd HSBC Nominees	4.0% 3.7%
J Graham**	3.4%
Acuity Capital	2.6%
JP Morgan Nominees Aus.	2.3%
M Dilizia Acewood Investments**	2.1% 1.8%
Querion Citicorp Nominees	1.2% 1.1%

ASX code

Shares on issue 2 March 2021

Share price 2 March 2021

Market Cap (approx.) 2 March 2021

Cash and deposits 31 December 2020

==> picture [61 x 45] intentionally omitted <==

RCE

173.77 million

USD $0.81 AUD $1.035

USD $140 million AUD $179 million

USD $18.63 million AUD $23.59 million

ASX:RCE 6 months

==> picture [326 x 125] intentionally omitted <==

USD 0.16c - $1.48 AUD 0.21c – $1.875

Trading range 52 week

Average daily volume 3 months Debt Nil

290.91K

Inventor & Former Head of J&J Research (Australasia)

** Held by Executive Directors

AUD converted to USD on 3 March 2021 at $1 AUD = $0.78 USD*

Board and Management Structure

==> picture [61 x 45] intentionally omitted <==

Dr John Prendergast – Non-Executive Chairman

BSc (Hons), MSc (UNSW), PhD (UNSW), CSS (HU)

US based, current Chairman and Co-founder of Palatin Technologies, Inc. (NYSE: PTN) and Lead Director of Heat Biologics, Inc. (NASDAQ: HTBX) – extensive experience in the international commercialisation of pharmaceutical technologies

James Graham – Managing Director & Chief Executive Officer

BCom (Entrepreneurship), GAICD

5 years as former Executive Director

Invested along-side shareholders in most capital rounds since inception. Background in marketing, business development and commercialisation of earlystage technologies.

Dr Alan Dunton – Non-Executive Director

BSc (BioChem) Hons, M.D. (NYU)

US based, Director of Palatin Technologies. Over three decades of senior pharmaceutical experience incl. President and MD of Janssen Research Foundation (J&J Research). Dr Dunton has advanced a number of blockbuster antibiotics through regulatory review and commercialization at fortune 500 companies including J&J and Roche.

Alistair McKeough – Company Secretary (Outsourced – Automic Group) Alistair is a qualified lawyer and Principal of Automic Legal Pty Ltd, Alistair has broad experience as a commercial litigator and Company Secretary to ASX Listed companies

Justin Reynolds – CFO (Outsourced - Pitcher Partners Sydney)

Justin is a qualified accountant and Partner of Pitcher Partners Sydney, Justin has broad experience covering all areas of accounting, taxation and assurance. Justin’s areas of expertise are business services and outsourced accounting

Arthur Kollaras – Principal Engineer & Head of Manufacturing

BSc Beng (Chem), PhilEng (Enviro), MIEAust, MISPE

Highly qualified in chemical engineering and microbiology, has significant experience taking a new technology concept to pilot plant and full-scale FDA standards and production internationally

Dr David Bowers – Chair of Clinical Advisory Committee

Leading spinal injury physician at Royal North Shore Hospital. Dr Bowers has a specialist interest in the treatment of complex and life-threatening antibiotic resistant infections, particularly among patients with severe spinal cord injuries.

Michele Dilizia – Executive Director & Chief Scientific Officer

BSc (Med Sci), Grad Dip Bus (Mkting), BA (Journ), GAICD, MASM

Co-inventor and qualified medical scientist; specialisation in medical microbiology and regulatory affairs

Dr Justin Ward – Executive Director & Principal Quality Chemist

Professor Philip Sutton – Head of H. pylori Development Program

Global infectious disease expert with over 30 years of research and industry experience, having served as former Head of Immunology at CSL Ltd in Melbourne. Chief Editor of textbook “ Helicobacter pylori in the 21[st] Century” and has co-authored 92 manuscripts published in peerreviewed journals. Professor Sutton currently leads Mucosal Immunology Group at Murdoch Children’s Research Institute.

BSc (Chem), PhD (Chem), MRACI, CChem

A quality control expert who has worked with leading pharmaceutical companies, he is bringing Recce’s research and development, and manufacturing up to US FDA requirements

==> picture [61 x 38] intentionally omitted <==

==> picture [97 x 30] intentionally omitted <==

==> picture [61 x 45] intentionally omitted <==

RECCE[®] – Multiple Anti-Infective Applications Recce’s technology enjoys the added opportunity of multiple markets and product categories.

==> picture [621 x 308] intentionally omitted <==

==> picture [56 x 56] intentionally omitted <==

==> picture [51 x 71] intentionally omitted <==

==> picture [72 x 61] intentionally omitted <==

==> picture [67 x 33] intentionally omitted <==

==> picture [61 x 38] intentionally omitted <==

==> picture [97 x 30] intentionally omitted <==

Estimated timelines/indications are subject to change in development plans and regulatory requirements/clarifications

*FIH – First-in-human

Natural Antibiotics vs Synthetic Antibiotics

==> picture [61 x 45] intentionally omitted <==

==> picture [65 x 68] intentionally omitted <==

==> picture [31 x 18] intentionally omitted <==

==> picture [81 x 93] intentionally omitted <==

==> picture [8 x 9] intentionally omitted <==

==> picture [8 x 10] intentionally omitted <==

==> picture [8 x 9] intentionally omitted <==

Pre-formed natural superbugs

All Fungi or Bacteria based

‒ “ Penicillin allergy is the most common drug allergy and is reported in up to 15 percent of

hospitalized patients

Only as good as what’s found in nature

Natural Antibiotics

==> picture [8 x 9] intentionally omitted <==

Has always had naturally occurring superbugs, now multiplying out of control!

==> picture [69 x 129] intentionally omitted <==

==> picture [56 x 43] intentionally omitted <==

==> picture [37 x 70] intentionally omitted <==

Synthetic Antibiotics

==> picture [61 x 38] intentionally omitted <==

==> picture [97 x 30] intentionally omitted <==

==> picture [7 x 9] intentionally omitted <==

==> picture [7 x 8] intentionally omitted <==

==> picture [7 x 9] intentionally omitted <==

NO pre-formed natural superbugs

Entirely man-made and designed with purpose

Universal Mechanism of Action - detailed experimentation demonstrates it does not succumb to superbugs

Contains only what we want - not reliant on what’s found in nature

Broad Spectrum capability and maintains its activity even with repeated use!

https://www.uptodate.com/contents/choice-of-antibiotics-in-penicillin-allergic-hospitalized-patients/abstract/1

Sepsis – it’s a big problem!

==> picture [61 x 45] intentionally omitted <==

One in three patients who die in hospital have sepsis 3

48.9 million incident cases of sepsis recorded worldwide1

11 million sepsis related deaths recorded2

==> picture [93 x 93] intentionally omitted <==

==> picture [101 x 75] intentionally omitted <==

==> picture [106 x 68] intentionally omitted <==

==> picture [81 x 61] intentionally omitted <==

==> picture [78 x 61] intentionally omitted <==

==> picture [85 x 61] intentionally omitted <==

==> picture [108 x 61] intentionally omitted <==

==> picture [10 x 10] intentionally omitted <==

==> picture [10 x 11] intentionally omitted <==

==> picture [10 x 10] intentionally omitted <==

Sepsis is a life-threatening inflammatory response to infection that has spread in the body.

4 ‒ Kills more people in the US than prostate , breast and HIV/AIDS combined. Has been the most expensive condition to treat in the last 8 years - double the 5 average cost per stay across all other conditions . Currently no drug therapies specifically for the treatment of sepsis. 6

1,2,3 – The Lancet
4 – BioMed Central
5 – University of Texas
6 – International Medicine Journal RACP

==> picture [61 x 38] intentionally omitted <==

==> picture [97 x 30] intentionally omitted <==

RECCE[®] 327 Phase I Human Clinical Trial

==> picture [61 x 45] intentionally omitted <==

Human safety and tolerability study to assess IV infusion of RECCE[®] 327 in 48 healthy subjects as a single ascending dose

==> picture [9 x 10] intentionally omitted <==

==> picture [132 x 95] intentionally omitted <==

==> picture [131 x 97] intentionally omitted <==

Phase I trial agreement with leading clinical research organization PAREXEL

==> picture [9 x 10] intentionally omitted <==

Trial will be held at CMAX Clinical Research – an independent trial facility

==> picture [9 x 10] intentionally omitted <==

Dispatched to Clinical Trial Facility (CMAX) Placebo and RECCE 327 (I.V.) via Recce’s Manufacturing facility (Sydney)

Facility meets international regulatory authority data entry and quality requirements including European Medicines Agency and US FDA

==> picture [9 x 10] intentionally omitted <==

==> picture [228 x 135] intentionally omitted <==

Formal subject recruitment to open for enrolments shortly

==> picture [9 x 10] intentionally omitted <==

CMAX has more than 30,000 registered patient volunteers on file Patient screened Q1, 2021

==> picture [9 x 10] intentionally omitted <==

==> picture [241 x 67] intentionally omitted <==

==> picture [61 x 38] intentionally omitted <==

CMAX Phase I Clinical Unit

==> picture [97 x 30] intentionally omitted <==

==> picture [61 x 45] intentionally omitted <==

RECCE[®] Antibiotics – Curative & Preventative IV Studies*

Number of mice that survived Sepsis from S. aureus (superbug)

Infection in mice from S. pyogenes

==> picture [284 x 181] intentionally omitted <==

==> picture [284 x 196] intentionally omitted <==

==> picture [228 x 21] intentionally omitted <==

----- Start of picture text -----

RECCE [®] 327 Oxacillin No treatment
132 mg/kg 500 mg/kg
----- End of picture text -----

All ten mice treated with RECCE[®] antibiotic survived Nine mice treated with efficacious dose of Oxacillin (500 mg/kg) survived

==> picture [7 x 8] intentionally omitted <==

Four mice that had no treatment at all, survived

==> picture [7 x 8] intentionally omitted <==

Results from an independent laboratory in USA

==> picture [61 x 38] intentionally omitted <==

==> picture [97 x 30] intentionally omitted <==

==> picture [7 x 8] intentionally omitted <==

One group of ten mice were administered a 167 mg/kg dose of RECCE [®] 327 at 0 hours. Second group received no antibiotic.
Both groups inoculated with the S. pyogenes burden into the bloodstream.
Mice results first monitored after 12 hours allowing bacteria to develop and establish an infection.

Bacteria in the blood were rapidly killed and unable to establish an infection in the kidneys of mice who received RECCE[®] 327.

==> picture [61 x 45] intentionally omitted <==

Single Dose and Range-Finding Repeat Dosing - Rats

==> picture [322 x 146] intentionally omitted <==

==> picture [239 x 206] intentionally omitted <==

No Observed Adverse Effect Level (NOAEL) of 24-hour 500mg/kg (10x indicated efficacious dose)

==> picture [7 x 8] intentionally omitted <==

Phase Ia (24-hour), Phase Ib (24-hour over 7 days)

==> picture [7 x 8] intentionally omitted <==

A separate single 24-hour intravenous infusion administration of RECCE [®] 327 up to 12,000 mg/kg over the course of 7-days was carried out.

==> picture [6 x 8] intentionally omitted <==

Results of up 12,000 mg/kg/day was well tolerated from Days 1 to 4 (inclusive); with no mortalities or clinical signs.

==> picture [6 x 8] intentionally omitted <==

24-hour dosing up to 4,000 mg/kg (80x indicated efficacious dose) in Dogs well tolerated.

==> picture [7 x 8] intentionally omitted <==

RECCE[®] 327 is indicated to be efficacious from as little as 50mg/kg and here shows tolerability can be sustained over at least 7 days of continuous daily exposure at doses up to and including 500 mg/kg.

==> picture [7 x 8] intentionally omitted <==

==> picture [61 x 38] intentionally omitted <==

==> picture [97 x 30] intentionally omitted <==

Single Dose and Range-Finding Repeat Dosing - Dogs

No Observed Adverse Effect Level (NOAEL) of 24-hour 500mg/kg (10x indicated efficacious dose)

==> picture [7 x 9] intentionally omitted <==

Phase Ia (24-hour), Phase Ib (24-hour over 7 days)

==> picture [7 x 8] intentionally omitted <==

A single 24-hour intravenous infusion administration of RECCE[® ] 327 up to 4000 mg/kg and 7-day continuous intravenous infusion administration of RECCE[®] 327 up to 500 mg/kg/day were well tolerated; with no mortalities, clinical signs, changes in body weight, coagulation, clinical chemistry or salient macroscopic abnormalities.

==> picture [7 x 9] intentionally omitted <==

RECCE[®] 327 is indicated to be efficacious from as little as 50mg/kg

==> picture [7 x 9] intentionally omitted <==

Therapeutic dose window appears considerably wider than Vancomycin and other antibiotics.

==> picture [7 x 8] intentionally omitted <==

==> picture [61 x 45] intentionally omitted <==

==> picture [410 x 169] intentionally omitted <==

RECCE[®] 327 Phase I/II Topical Human Trial in burn wound infections

==> picture [61 x 45] intentionally omitted <==

==> picture [8 x 9] intentionally omitted <==

==> picture [8 x 10] intentionally omitted <==

==> picture [8 x 9] intentionally omitted <==

The topical study will assess RECCE[®] 327 as a broadspectrum antibiotic for patients with Gram-positive and Gram-negative bacterial burn wound infections

Sponsored by the South Metropolitan Health Service, Department of Health, Government of Western Australia

Fiona Stanley Hospital nominated as the study site

==> picture [8 x 9] intentionally omitted <==

Principal Investigator Professor Fiona Wood

==> picture [8 x 10] intentionally omitted <==

Dr Wood pioneered the innovative the worlds-first ‘sprayon skin’ technique, which greatly reduces permanent scarring in burns victims.

==> picture [8 x 9] intentionally omitted <==

Over 14 days, 10 patients will receive RECCE[®] 327 daily while a further 20 receive treatment 3 times per week

==> picture [271 x 204] intentionally omitted <==

Phase I/II clinical trial approved by Human Research Ethics Committee

==> picture [8 x 9] intentionally omitted <==

==> picture [61 x 38] intentionally omitted <==

==> picture [97 x 30] intentionally omitted <==

==> picture [233 x 44] intentionally omitted <==

Topical Efficacy – Wound Infection & Contraction

==> picture [61 x 45] intentionally omitted <==

Superbug Methicillin-Resistant S. aureus (MRSA) in Rats

==> picture [316 x 193] intentionally omitted <==

The Study Director noted: “ RECCE[®] 327 (100 µl (19.15 mg/ml), topical, once daily, over three days), and Soframycin (30 mg, topical, twice daily, Q=12hr, over three days) showed a significant reduction wound on day four (p<0.05) when compared to day one, when compared to the vehicle control .”

==> picture [258 x 196] intentionally omitted <==

The Study Director noted: “ RECCE [®] 327 (100 µl (19.15 mg/ml), topical, once daily over three days) showed significant reduction in bacterial load on day four when compared to day one. Soframycin (30 mg, topical, twice daily, Q=12hr, over three days), the current standard of care antibiotic did not show significant efficacy on day four...”

==> picture [61 x 38] intentionally omitted <==

==> picture [97 x 30] intentionally omitted <==

*Significantly different from vehicle control (p<0.05, 1-way ANOVA) Results from an independent laboratory in USA

RECCE[®] 435 Pre-clinical Studies Program with H. pylori

Murdoch Children’s Research Institute (MCRI) to evaluate in-vivo antimicrobial activity of RECCE[®] 435 oral formulation against Helicobacter pylori (H. pylori) in pre-clinical studies program

==> picture [7 x 8] intentionally omitted <==

RECCE[®] 435 is a new broad-spectrum synthetic polymer antibiotic formulated for oral use

==> picture [7 x 9] intentionally omitted <==

Study led by H. pylori infectious disease expert Professor Philip Sutton

==> picture [7 x 8] intentionally omitted <==

Research program will be carried out by Mucosal Immunology Group at the MCRI Royal Children’s Hospital

==> picture [7 x 8] intentionally omitted <==

MCRI is one of the top three child health research institutes worldwide for research quality and impact

==> picture [7 x 9] intentionally omitted <==

Recce and MCRI will work together on the oral antibiotic dosing program with a particular focus on optimal dosing and the effect of RECCE[®] 435

==> picture [7 x 8] intentionally omitted <==

Anticipated completion in approximately 12 months, at which time Recce will pursue a human clinical trial

==> picture [7 x 9] intentionally omitted <==

==> picture [61 x 38] intentionally omitted <==

==> picture [97 x 30] intentionally omitted <==

==> picture [61 x 45] intentionally omitted <==

==> picture [8 x 9] intentionally omitted <==

==> picture [61 x 45] intentionally omitted <==

RECCE[®] 435 Efficacy Against H. pylori

==> picture [341 x 239] intentionally omitted <==

New RECCE [®] 435 oral showed dose-dependent and significant efficacy against Helicobacter pylori (H. pylori) bacteria
Bacteria isolated from a patient with a duodenal ulcer compared to control vehicle in independent study model in rats

==> picture [8 x 9] intentionally omitted <==

Five groups of 10 rats each were observed. Three groups were treated with varying doses of RECCE [®] 435 (250, 500, 1,000 mg/kg)
Dose-dependent efficacy was seen at all doses with significant reduction in bacterial load.

==> picture [8 x 10] intentionally omitted <==

High solubility and antibacterial effect supportive of a ‘targeted’ oral therapy for stomach infection

==> picture [8 x 9] intentionally omitted <==

Study assessed a combination of two broad spectrum antibiotics being used – Amoxicillin and Clarithromycin.

==> picture [61 x 38] intentionally omitted <==

==> picture [97 x 30] intentionally omitted <==

==> picture [61 x 45] intentionally omitted <==

RECCE[®] 435 Safety Oral Study

==> picture [283 x 252] intentionally omitted <==

Additional independent study was undertaken

==> picture [9 x 11] intentionally omitted <==

Purpose of the study examined the safety oral dosing of RECCE [®] 435 up to 500 mg/kg

==> picture [9 x 10] intentionally omitted <==

Compound was administered to groups of five mice each twice daily for seven days compared to water-only administration

==> picture [9 x 11] intentionally omitted <==

Data indicates their feeding habits, which contributes to weight gain

==> picture [9 x 10] intentionally omitted <==

No negative impact

==> picture [9 x 11] intentionally omitted <==

Supports overall general and gastrointestinal health

==> picture [9 x 11] intentionally omitted <==

==> picture [352 x 98] intentionally omitted <==

==> picture [61 x 38] intentionally omitted <==

==> picture [97 x 30] intentionally omitted <==

SARS-CoV-2 Antiviral Program

RECCE[®] 327 compound selected as Priority 1 candidate group for testing in SARS-CoV-2 Antiviral Program. The program is run by a scientific Australian Government agency and a world class institute focused on infection and immunity. Compounds were chosen by a Science Selection Panel including field experts in the areas of: Virology, Antivirals, Medicinal Chemistry & Clinical Trials of Antiviral drugs. Therapeutic anti-viral treatment focus with added potential benefit against secondary bacterial infections. All intellectual property rights are retained by the Company

==> picture [9 x 11] intentionally omitted <==

==> picture [61 x 38] intentionally omitted <==

==> picture [97 x 30] intentionally omitted <==

==> picture [61 x 45] intentionally omitted <==

==> picture [203 x 155] intentionally omitted <==

==> picture [56 x 53] intentionally omitted <==

SARS-CoV-2 Antiviral Program

==> picture [61 x 45] intentionally omitted <==

Virus Titres

RECCE[®] 327 showed encouraging efficacy in an in-vitro screening assay against SARS-CoV-2 virus

==> picture [8 x 10] intentionally omitted <==

RECCE[®] 327 advancing to Stage 1b ( confirmatory in-vitro testing and a cytotoxicity assessment )

==> picture [8 x 9] intentionally omitted <==

Positive control in this study was beta-d-N4 hydroxycytidine (NHC)

==> picture [8 x 9] intentionally omitted <==

A highly active anti-viral compound against SARS-CoV-2 in-vitro not approved for human use

==> picture [8 x 9] intentionally omitted <==

Stage 1b (confirmation and cytotoxicity) results expected Q1 2021

==> picture [8 x 9] intentionally omitted <==

US Gold Standard Ferret Study running in parallel – conducted by an independent contract research organisation

==> picture [8 x 9] intentionally omitted <==

==> picture [61 x 38] intentionally omitted <==

==> picture [97 x 30] intentionally omitted <==

==> picture [217 x 156] intentionally omitted <==

==> picture [213 x 156] intentionally omitted <==

==> picture [198 x 139] intentionally omitted <==

IC50 of test compound excluding the 3 lowest data points: 109.8 PPM Data extracted from study report

SARS-CoV-2 Antiviral Program

==> picture [61 x 45] intentionally omitted <==

==> picture [8 x 9] intentionally omitted <==

==> picture [8 x 10] intentionally omitted <==

==> picture [8 x 9] intentionally omitted <==

RECCE[®] 327 99.9% efficacious (3-log drop in viral genome copies) in confirmatory in-vitro screening assay against SARS-CoV-2

RECCE 327 RT-PCR and Cell Viability Data

==> picture [224 x 181] intentionally omitted <==

==> picture [232 x 182] intentionally omitted <==

Virucidal against SARS-CoV-2 with a positive safety profile

==> picture [8 x 9] intentionally omitted <==

SARS-CoV-2 virus no longer detectable by virus titration at 4,000ppm

Minimal toxicity to Vero cells

==> picture [8 x 10] intentionally omitted <==

No toxicity identifiable at 1,333ppm or less Positive control in this study was beta-d-N4 hydroxycytidine (NHC)

US in-vivo studies in parallel expanded to include new UK and South African COVID strains

==> picture [61 x 38] intentionally omitted <==

==> picture [97 x 30] intentionally omitted <==

SARS-CoV-2 International Study

==> picture [61 x 45] intentionally omitted <==

RECCE[®] 327 and RECCE[®] 529 have shown concentration-dependent reductions in the SARS-CoV-2 virus

==> picture [9 x 11] intentionally omitted <==

Concentrations of R327 and R529 tested, further indicated an excellent toxicity profile (<0.25%) on Vero (monkey) cells, in a separately related study

==> picture [9 x 11] intentionally omitted <==

COVID-19 studies have advanced to goldstandard animal in-vivo models (e.g. ferret)

==> picture [9 x 10] intentionally omitted <==

Multiple methods of administration for best chance of continued activity to target viral infection in the airways/lungs

==> picture [9 x 11] intentionally omitted <==

==> picture [61 x 38] intentionally omitted <==

==> picture [97 x 30] intentionally omitted <==

==> picture [340 x 262] intentionally omitted <==

==> picture [55 x 53] intentionally omitted <==

==> picture [16 x 16] intentionally omitted <==

SARS-CoV-2 Intranasal Study**

==> picture [61 x 45] intentionally omitted <==

RECCE[®] 327 and RECCE[®] 529 demonstrated dosedependent activity in-vivo against SARS-CoV-2 virus in Syrian golden hamsters

==> picture [7 x 9] intentionally omitted <==

Intranasal administration of both compounds supports multiple potential modes of administration against SARS-CoV-2

==> picture [7 x 9] intentionally omitted <==

Study consisted of five groups of eight hamsters , each receiving a different treatment

==> picture [7 x 8] intentionally omitted <==

Placebo control of saline nasal wash, low dose of R327 (200mg/kg), high dose of R327 (400mg/kg), low dose of R529 (100mg/kg), and high dose of R529 (200mg/kg)

==> picture [7 x 9] intentionally omitted <==

Data conveyed a mean log reduction within groups on Day 4 where low R529 dose achieved a log reduction in the order of 1.5 logs and a high dose of R327 achieved log reduction of 1.25 logs

==> picture [7 x 9] intentionally omitted <==

This hamster study is the first indication of the potential for nasal administration of Recce’s anti-infective compounds, specifically when used against viruses

==> picture [7 x 8] intentionally omitted <==

==> picture [61 x 38] intentionally omitted <==

==> picture [97 x 30] intentionally omitted <==

==> picture [379 x 129] intentionally omitted <==

Understanding logs (example of a small colony of 1 million MRSA bacteria)*

A 1-log kill reduces the colony to 100,000 MRSA bacteria after a 90% reduction

A 2-log kill reduces the colony to 10,000 bacteria after a 99% reduction

A 3-log kill reduces the colony to 1,000 bacteria after a 99.9% reduction

A 4-log kill reduces the colony to 100 bacteria after a 99.99% reduction

A 5-log kill reduces the colony to 10 bacteria after a 99.999% reduction

A 6-log kill reduces the colony to 1 MRSA bacterium after a 99.9999% reduction

==> picture [40 x 38] intentionally omitted <==

https://halosil.com/what-are-logs-and-why-do-they-matter-in-preventing-infections/ *Statistical significance was not assessed in this study

RECCE[®] 327 kills at practical speeds

==> picture [61 x 45] intentionally omitted <==

Standard Bacteria

==> picture [665 x 328] intentionally omitted <==

----- Start of picture text -----

S. aureus E. coli P. aeruginosa S. pyogenes C. difficile
20-60 minutes 20-60 minutes 3-24 hours 20-60 minutes 20-60 minutes
Superbugs
S. aureus E. coli P. aeruginosa
The same kill-rates
for standard bacteria
and their superbugs
20-60 minutes 20-60 minutes 3-24 hours
All concentrations of bacteria (germ) were 10 cfu/ml
Concentration of RECCE antibiotic was 1,000 ppm against all bacteria except P. aeruginosa 2,000 ppm was used against P. aeruginosa
----- End of picture text -----

RECCE[®] 327 Does Not Lose Activity!1

==> picture [61 x 45] intentionally omitted <==

Number of repetitive uses before displaying loss of antibiotic activity

==> picture [428 x 237] intentionally omitted <==

----- Start of picture text -----

RECCE [®] 327
----- End of picture text -----

1 After repetitive use, the commercial antibiotic loses activity; >25 repeats RECCE[®] 327 DOES NOT

==> picture [61 x 38] intentionally omitted <==

==> picture [97 x 30] intentionally omitted <==

*‘Commercial Antibiotic’ generates over US $10bn in revenue

RECCE[®] 327 Mechanism of Action in practice

==> picture [61 x 45] intentionally omitted <==

00:00 minutes

Before application of RECCE[®] 327, the E.coli bacteria cells are healthy, smooth and intact

E.coli Facts1

Part of the Enterobacteriaceae family
$1.2bn USD estimated attributable healthcare costs in 2017
CDC labels this bacteria as a Serious Threat
• 50% increase in cases since 2012

1CDC Antibiotic Resistance Report 2019

==> picture [61 x 38] intentionally omitted <==

==> picture [97 x 30] intentionally omitted <==

This is a high-definition electron microscope image generated in February 2017 by Dr Peta 24 Clode and Lyn Kirilak of the Centre for Microscopy, Characterisation and Analysis, University of Western Australia. It was taken to demonstrate RECCE[®] 327’s unique mechanism of action

RECCE[®] 327 Mechanism of Action in practice

==> picture [61 x 45] intentionally omitted <==

20 minutes

After application of RECCE[®] 327, the E.coli bacteria cell membrane begins to weaken and is disrupted

==> picture [168 x 60] intentionally omitted <==

----- Start of picture text -----

Burst! – others already
redundant and breaking
down
----- End of picture text -----

==> picture [61 x 38] intentionally omitted <==

==> picture [97 x 30] intentionally omitted <==

This is a high-definition electron microscope image generated in February 2017 by Dr Peta Clode and Lyn Kirilak of the Centre for Microscopy, Characterisation and Analysis, University of Western Australia. It was taken to demonstrate RECCE[®] 327’s unique mechanism of action 25

RECCE[®] 327 Mechanism of Action in practice

==> picture [61 x 45] intentionally omitted <==

180 minutes

==> picture [168 x 138] intentionally omitted <==

----- Start of picture text -----

Bacteria compromised –
now consumable by
healthy blood cells
----- End of picture text -----

E. coli bacteria cells (10e6 cfu/ml) having their outer membrane weakened – and bursting from treatment with RECCE[®] 327 (1000 ppm)

==> picture [61 x 38] intentionally omitted <==

==> picture [97 x 30] intentionally omitted <==

Patents and trademarks

==> picture [61 x 45] intentionally omitted <==

Recce’s patent portfolio includes more than 20 issued patents and patent applications in the world’s major markets, including the United States, Europe, Japan, China and Australia.

Patent Family 1 – Antimicrobial Polymers and Their Compositions

Family 1 group relates to the Company’s unique and highly economical manufacturing process and use of the polymer in treatment of diseases

==> picture [7 x 8] intentionally omitted <==

Patent Family 2 – Copolymer for use in Method of Treatment of a Parenteral Infection

Family 2 relates to the method of manufacture, administration and application to treat a broad range of common human infections.

==> picture [7 x 8] intentionally omitted <==

Patent Family 3 – Anti-Virus Agent and Method for Treatment of Viral Infection

Family 3 relates to a method of treatment of a broad range of viral infections, particularly parenteral viral infection

==> picture [7 x 8] intentionally omitted <==

==> picture [61 x 38] intentionally omitted <==

==> picture [97 x 30] intentionally omitted <==

Filed	Patent Family 1 Granted	Expiry	Patent Family 2	Expiry	Patent Family 3	Expiry	Patent Family 4	Trademarks registered
Australia	✓	2028	✓	2035	Pending	2037	Pending	✓
USA	✓	2029	✓	2035	Pending	2037	Pending	✓
Europe	✓	2028	✓	2035	Pending	2037	Pending	✓
Germany	✓	2028	✓	2035	Pending	2037	Pending	-
Spain	✓	2028	✓	2035	Pending	2037	Pending	-
France	✓	2029	✓	2035	Pending	2037	Pending	-
United	✓	2028	✓	2035	Pending	2037	Pending	-
Kingdom Italy	✓	2028	✓	2035	Pending	2037	Pending	-
Sweden	✓	2028	✓	2035	Pending	2037	Pending	-
Japan	✓	2028	✓	2035	✓	2037	Pending	✓
China	✓	2028	Pending	2035	Pending	2037	Pending	✓

Manufacturing and Production

==> picture [61 x 45] intentionally omitted <==

==> picture [394 x 264] intentionally omitted <==

Wholly owned, automated manufacturing facility in Sydney’s Macquarie Park

Raw materials plentiful and CHEAP – few $/KG No expensive waste – 99.9% product yield.

==> picture [8 x 10] intentionally omitted <==

==> picture [8 x 9] intentionally omitted <==

Automated manufacture process taking approximately 1 ¼ hours .

==> picture [8 x 9] intentionally omitted <==

500 doses per automated manufacture output in less than 1 hour/run

==> picture [8 x 10] intentionally omitted <==

==> picture [31 x 69] intentionally omitted <==

Currently producing in volumes to support planned Phase I & II clinical trials .

==> picture [8 x 9] intentionally omitted <==

Facility built to pharmaceutical specification. Packaging and labelling to international ‘tamper-proof’

==> picture [8 x 9] intentionally omitted <==

==> picture [61 x 38] intentionally omitted <==

==> picture [97 x 30] intentionally omitted <==

Investment summary

R327 Qualified Infectious Disease Product (QIDP) Designation

R327 Generating Antibiotics Proprietary technology as a Incentive Now (GAIN) Act new class of approved synthetic anti-infectives

R327 initial focus on sepsisFavourable legislative and potentially the first treatment financial landscape for sepsis

Experienced commercial management and board

==> picture [61 x 38] intentionally omitted <==

==> picture [97 x 30] intentionally omitted <==

==> picture [61 x 45] intentionally omitted <==

R327 addressing the most expensive condition faced by hospitals worldwide

Early commercialisation potential

Creating value by meeting Established manufacturing key milestones (volumes suitable for Ph I/II)

Last 6 Months of Announcements ASX: RCE

==> picture [61 x 45] intentionally omitted <==

==> picture [7 x 8] intentionally omitted <==

RCE Receives Innovation Connection Grant (1 Sep 2020) Positive and Concentration Dependent Efficacy Against SARS-CoV-2 (8 Sept 2020) R327 Phase I study, Aus CMAX Clinical Facility (10 Sept 2020) RCE Completes Successful Capital raise $27.95m (23 Sept 2020) MCRI agreement signed, R435 against H. pylori (30 Sept 2020) R&D Rebate Received (5 Oct 2020) HREC Approval to Start Phase I/II Topical Burns Wound Study (16 Oct 2020) Encouraging Results Against SARS-CoV-2 Virus from Australia Study (10 Nov 2020) Anti-viral Patent Granted in Japan for RCE Anti-Infectives (23 Nov 2020) Recce Awarded Aus. Industry Advanced Overseas Antibacterial finding (26 Nov 2020) Recce awarded Aus. Industry Advanced Overseas Anti-viral finding (8 Dec 2020) Positive Intranasal Animal Data Against SARS-CoV-2 in US Study (23 Dec 2020) R&D Incentive Rebate Received (3 February 2021) Further Encouraging COVID Results at Doherty (12 Feb 2021) Fiona Stanley Hospital Phase I/II Clinical Trial Agreement (16 Feb 2021) Recce Applies for Dual Listing on Frankfurt Stock Exchange (24 Feb 2021)

==> picture [226 x 96] intentionally omitted <==

==> picture [227 x 43] intentionally omitted <==

==> picture [61 x 38] intentionally omitted <==

==> picture [97 x 30] intentionally omitted <==

==> picture [61 x 45] intentionally omitted <==

Thank you

James Graham

Managing Director and Chief Executive Officer Recce Pharmaceuticals

ASX:RCE

==> picture [8 x 9] intentionally omitted <==

==> picture [9 x 9] intentionally omitted <==

+61 2 9256 2572 [email protected]

==> picture [61 x 38] intentionally omitted <==

recce.com.au

AI assistant

RECCE PHARMACEUTICALS LTD — Investor Presentation 2021

65669_rns_2021-03-09_6640e1ce-2611-4f78-bade-ebb1ced24604.pdf

ASX Announcement

Recce Pharmaceuticals Presenting at the H.C. Wainwright Global Life Sciences Conference

For further information please contact:

Disclaimer

DISCLAIMER

FUTURE MATTERS

US DISCLOSURE

About Recce Pharmaceuticals Ltd

Recce Pharmaceuticals Ltd - Capital Structure

Snapshot***

RCE

173.77 million

ASX:RCE 6 months

Board and Management Structure

Dr John Prendergast – Non-Executive Chairman

BSc (Hons), MSc (UNSW), PhD (UNSW), CSS (HU)

James Graham – Managing Director & Chief Executive Officer

BCom (Entrepreneurship), GAICD

Dr Alan Dunton – Non-Executive Director

BSc (BioChem) Hons, M.D. (NYU)

Justin Reynolds – CFO (Outsourced - Pitcher Partners Sydney)

Arthur Kollaras – Principal Engineer & Head of Manufacturing

Dr David Bowers – Chair of Clinical Advisory Committee

Michele Dilizia – Executive Director & Chief Scientific Officer

BSc (Med Sci), Grad Dip Bus (Mkting), BA (Journ), GAICD, MASM

Dr Justin Ward – Executive Director & Principal Quality Chemist

Professor Philip Sutton – Head of H. pylori Development Program

BSc (Chem), PhD (Chem), MRACI, CChem

Natural Antibiotics vs Synthetic Antibiotics

Natural Antibiotics

Sepsis – it’s a big problem!

RECCE[®] 327 Phase I Human Clinical Trial

RECCE[®] Antibiotics – Curative & Preventative IV Studies*

Single Dose and Range-Finding Repeat Dosing - Rats

Single Dose and Range-Finding Repeat Dosing - Dogs

No Observed Adverse Effect Level (NOAEL) of 24-hour 500mg/kg (10x indicated efficacious dose)

RECCE[®] 327 Phase I/II Topical Human Trial in burn wound infections

Fiona Stanley Hospital nominated as the study site

Principal Investigator Professor Fiona Wood

Topical Efficacy – Wound Infection & Contraction

RECCE[®] 435 Pre-clinical Studies Program with H. pylori

RECCE[®] 435 Efficacy Against H. pylori

RECCE[®] 435 Safety Oral Study

SARS-CoV-2 Antiviral Program

SARS-CoV-2 Antiviral Program

Virus Titres

SARS-CoV-2 Antiviral Program

SARS-CoV-2 International Study

SARS-CoV-2 Intranasal Study**

RECCE[®] 327 kills at practical speeds

Standard Bacteria

Number of repetitive uses before displaying loss of antibiotic activity

RECCE[®] 327 Mechanism of Action in practice

00:00 minutes

E.coli Facts1

1CDC Antibiotic Resistance Report 2019

RECCE[®] 327 Mechanism of Action in practice

RECCE[®] 327 Mechanism of Action in practice

180 minutes

Patents and trademarks

Recce’s patent portfolio includes more than 20 issued patents and patent applications in the world’s major markets, including the United States, Europe, Japan, China and Australia.

Patent Family 2 – Copolymer for use in Method of Treatment of a Parenteral Infection

Patent Family 3 – Anti-Virus Agent and Method for Treatment of Viral Infection

Manufacturing and Production

Wholly owned, automated manufacturing facility in Sydney’s Macquarie Park

Investment summary

Last 6 Months of Announcements ASX: RCE

Thank you

James Graham

More from RECCE PHARMACEUTICALS LTD

RECCE PHARMACEUTICALS LTD Investor Presentation 2021